Inclusion Criteria:  Patients ≥ 40 and < 80 years of age; Chronic symptomatic HFpEF defined as follows: left ventricular ejection fraction (LVEF) > or = 45% by echocardiography within 6 months prior to screening visit; Stable clinically and therapeutically for at least 1 month before enrolment; *NYHA functional class II to IV; Evidence of structural heart disease defined by at least 1 of the following echocardiography findings: LV hypertrophy (i.e. septal or posterior wall thickness ≥1.1 cm) or left atrial enlargement (i.e., width ≥3.8 cm, length ≥5.0 cm, area ≥20 cm2, volume ≥55 ml, or volume index ≥29 ml/m2); an NT-proBNP of ≥600 pg/ml if in sinus rhythm, and ≥1800 pg/ml if in atrial fibrillation;  and at least one of the following criteria defining chronic enhanced inflammatory milieu:  Obesity, defined as body mass index (BMI) > 30kg/m2, Diabetes mellitus, Evidence of pathological systemic inflammation including: high hs-CRP levels (hs-CRP>5mg/L), or the combination of high neutrophil count and low lymphocyte count (Neutrophil to Lymphocyte Ratio >3).  Exclusion Criteria:  Patients > 80 years of age; Any prior echocardiographic measurement of LVEF <45%; Presence of clinical, biological or echocardiography signs of cardiac amyloidosis; Presence of hemodynamically significant valvular heart disease in the opinion of the investigator; Presence of active infection within the 3 months prior to enrolment; Acute decompensated HF, acute coronary syndrome (including myocardial infarction), cardiac surgery, other major cardiovascular surgery, or urgent percutaneous coronary intervention (PCI) within the 3 months prior to baseline visit or an elective PCI within 30 days prior to baseline visit; Current acute decompensated HF requiring augmented therapy with diuretic agents, vasodilator agents, and/or inotropic drugs; Changes in diuretics and / or renin-angiotensin-aldosterone system (RAAS) inhibitors regimen within 30 days prior to visit; History of hypersensitivity to colchicine; Life-threatening or uncontrolled dysrhythmia, including symptomatic or sustained ventricular tachycardia and atrial fibrillation or atrial flutter with a resting ventricular rate >120 beats per minute; Any surgical or medical condition that in the opinion of the investigator may place the patient at higher risk from his/her participation in the study or is likely to prevent the patient from complying with the requirements of the study or completing the study; Evidence of hepatic disease as determined by any 1 of the following: serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) values exceeding 3× the upper limit of normal, bilirubin>1.5 mg/dL (>25.65 μmol/L) at baseline visit; or patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease; Patients with estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m2 as calculated by the Modification in Diet in Renal Disease (MDRD) formula at baseline visit; History or presence of any other disease with a life expectancy of <1 year; Women of child-bearing potential; Patient with inflammatory bowel disease (Crohn's disease or ulcerative colitis) or patient with chronic diarrhea; Patient with pre-existent progressive neuromuscular disease; Patient currently taking colchicine for other indications (mainly chronic indications represented by Familial Mediterranean Fever or gout); Patients currently under long-term anti-inflammatory medication for a chronic condition (steroids, NSAIDS); Patient considered by the investigator, for any reason, to be an unsuitable candidate for the study.